{
  "source": "PA-Notification-Vascepa.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1072-13\nProgram Prior Authorization/Notification\nMedication Vascepa® (icosapent ethyl)*\nP&T Approval Date 7/2010, 5/2011, 4/2012, 11/2012, 8/2013, 7/2014, 7/2015, 7/2016, 7/2017,\n7/2018, 10/2019, 2/2020, 3/2021, 3/2022, 3/2023, 3/2024, 3/2025\nEffective Date 6/1/2025\n1. Background:\nVascepa® (icosapent ethyl)* is indicated as adjunctive therapy to diet and exercise to reduce\ntriglyceride (TG) levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.\nVascepa* is also indicated as an adjunct to maximally tolerated statin therapy to reduce the risk\nof myocardial infarction, stroke, coronary revascularization, and unstable angina requiring\nhospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and either\nestablished cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for\ncardiovascular disease.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Severe Hypertriglyceridemia\na. Vascepa* will be approved based on both of the following criteria:\n1) Diagnosis of severe hypertriglyceridemia (pre-treatment triglyceride level of greater\nthan or equal to 500 mg/dL)\n-AND-\n2) Patient is on an appropriate lipid-lowering diet and exercise regimen\nAuthorization will be issued for 12 months\n2. Cardiovascular risk reduction\na. Vascepa* will be approved based on all of the following criteria:\n1) Diagnosis hypertriglyceridemia (pre-treatment triglyceride level ≥ 150 mg/dL)\n-AND-\n2) Patient is receiving maximally tolerated statin therapy\n-AND-\n3) Used to reduce the risk of myocardial infarction, stroke, coronary revascularization,\n© 2025 UnitedHealthcare Services, Inc.\n1\nand unstable angina requiring hospitalization\n-AND-\n4) One of the following:\na) Established cardiovascular disease (CVD)\n- OR-\nb) Both of the following:\ni. Diagnosis of diabetes mellitus\n-AND-\nii. Two additional risk factors for cardiovascular disease, for example:\n1. Men ≥55",
    "\na) Established cardiovascular disease (CVD)\n- OR-\nb) Both of the following:\ni. Diagnosis of diabetes mellitus\n-AND-\nii. Two additional risk factors for cardiovascular disease, for example:\n1. Men ≥55 years and women ≥65 years\n2. Cigarette smoker or stopped smoking within the past 3 months\n3. Hypertension (pretreatment blood pressure ≥140 mmHg systolic or ≥90\nmmHg diastolic)\n4. HDL-C ≤40 mg/dL for men or ≤50 mg/dL for women\n5. High-sensitivity C-reactive protein >3.0 mg/L\n6. Creatinine clearance >30 and <60 mL/min\n7. Retinopathy\n8. Micro- or macro-albuminuria\n9. Ankle-brachial index (ABI) <0.9 without symptoms of intermittent\nclaudication\nAuthorization will be issued for 12 months\nB. Reauthorization\n1. Severe Hypertriglyceridemia\na. Vascepa* will be approved based on both of the following criteria:\n1) Documentation of positive clinical response to therapy\n-AND-\n2) Patient is on an appropriate lipid-lowering diet and exercise regimen\nAuthorization will be issued for 12 months\n2. Cardiovascular risk reduction\na. Vascepa* will be approved based on both of the following criteria:\n© 2025 UnitedHealthcare Services, Inc.\n2\n1) Documentation of positive clinical response to therapy\n-AND-\n2) Patient is receiving maximally tolerated statin therapy\nAuthorization will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim\nlogic. Use of automated approval and re-approval processes varies by program and/or\ntherapeutic class.\n*Vascepa (brand and generic) is typically excluded from coverage. Tried/Failed criteria may be in\nplace. Please refer to plan specifics to determine exclusion status\n4. Referen",
    "d/or\ntherapeutic class.\n*Vascepa (brand and generic) is typically excluded from coverage. Tried/Failed criteria may be in\nplace. Please refer to plan specifics to determine exclusion status\n4. References:\n1. Vascepa [package insert]. Bridgewater, NJ: Amarin Pharma Inc.; September 2021.\n2. Orringer, CE, Jacobson, TA, Maki, KC. National Lipid Association Scientific Statement on\nthe use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-\nhigh ASCVD risk. J Clin Lipidol. 2019;13(6):860-72.\nProgram Prior Authorization/Notification - Vascepa® (icosapent ethyl)\nChange Control\nDate Change\n8/2013 Removed grandfathering criteria and replaced with reauthorization\ncriteria. Changed criteria to note documentation of hypertriglyceridemia\nand added criteria to require patient to be on an appropriate lipid-\nlowering diet and exercise regimen.\n7/2014 Added Omtryg and Epanova to criteria. Removed notation that\nVascepa typically excluded from coverage.\n7/2015 Updated references. Added notation that multi-source brand Lovaza is\ntypically excluded from coverage.\n7/2016 Updated to mirror indications and usage section in prescribing\ninformation. Added note that criteria applies to brand and generic\nLovaza. Updated references.\n7/2017 Annual review. Updated references.\n7/2018 Annual review. Removed Epanova and Omtryg since products have\nnever launched.\n10/2019 Annual review. Updated references.\n2/2020 Removed Lovaza from criteria. Added new indication for Vascepa and\nupdated references.\n3/2021 Modified pre-treatment triglyceride levels for cardiovascular risk\n© 2025 UnitedHealthcare Services, Inc.\n3\nreduction. Noted that Vascepa is typically excluded from coverage.\n3/2022 Annual review. No changes.\n3/2023 Annual review. Added state mandate language. Updated references.\n3/2024 Annual review. No changes.\n3/2025 Annual review. No changes.\n© 2025 UnitedHealthcare Services, Inc.\n4"
  ]
}